Ultragenyx Pharmaceutical (RARE) Q2 FY2026 earnings: revenue $214 million, up 28.1% on the year
Ultragenyx Pharmaceutical Inc. (RARE) reported revenue of $214 million for Q2 FY2026, the quarter ended 30 June 2026, up 28.1% on the same quarter a year earlier. Net income was -$92 million, and diluted earnings per share $-0.90. The figures are the company's own, from the 10-Q it filed with the SEC on 5 August 2026.
Revenue$214 millionup 28.1%
Net income-$92 million
Diluted EPS$-0.90
QuarterQ2 FY2026ended 30 June 2026
The quarter, against the one before and a year earlier
| Line | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | Change on the year |
|---|---|---|---|---|
| Revenue | 214 | 136 | 167 | +28.1% |
| Research and development | 167 | 187 | 165 | +1.4% |
| Selling, general and administrative | 88.0 | 88.0 | 87.0 | +1.1% |
| Operating income | -75.0 | -169 | -108 | n/a |
| Operating margin | -35.0% | -124.3% | -64.6% | |
| Pre-tax income | -91.0 | -184 | -114 | n/a |
| Income tax | 1.0 | 1.0 | 1.0 | +0.0% |
| Net income | -92.0 | -185 | -115 | n/a |
| Net margin | -43.0% | -136.0% | -68.8% | |
| Diluted EPS | -$0.90 | -$1.84 | -$1.17 | n/a |
$ million except per share.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.Cash flow and capital returned
| Line | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | Change on the year |
|---|---|---|---|---|
| Operating cash flow | -97.0 | -197 | -108 | n/a |
| Capital expenditure | 1.0 | 1.0 | 2.5 | -59.3% |
| Free cash flow | -98.0 | -198 | -111 | n/a |
| Free cash flow margin | -45.8% | -145.6% | -66.3% | |
| Cash from investing | 44.0 | -49.0 | 71.2 | -38.2% |
| Cash from financing | n/a | n/a | 83.6 | n/a |
| Depreciation and amortisation | 8.0 | 8.0 | 8.6 | -7.2% |
| Share-based compensation | 34.0 | 0.0 | 38.6 | -12.0% |
| Diluted shares, weighted | 102m | 101m | 98m | +3.5% |
| Shares outstanding at period end | 99m | 98m | 96m | +2.3% |
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet at quarter end
| Line | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | Change on the year |
|---|---|---|---|---|
| Shareholders' equity | -291 | -236 | 151 | n/a |
| Redeemable equity | 7.0 | 7.0 | 7.0 | +0.0% |
| Debt | 0.0 | 0.0 | 0.0 | n/a |
| Operating lease liabilities | n/a | n/a | 24.5 | n/a |
| Other liabilities | 1,548 | 1,525 | 1,123 | +37.8% |
| Total liabilities and equity | 1,264 | 1,296 | 1,306 | -3.2% |
| Fixed assets | 235 | 239 | 256 | -8.1% |
| Goodwill | 44.0 | 44.0 | 44.4 | -0.9% |
| Intangible assets | 172 | 174 | 175 | -1.6% |
| Investments | 311 | 359 | 363 | -14.3% |
| Cash and equivalents | 125 | 175 | 176 | -29.1% |
| Receivables | 200 | 121 | 124 | +60.7% |
| Inventory | 59.0 | 55.0 | 46.5 | +26.9% |
| Other assets | 118 | 129 | 121 | -2.8% |
| Total assets | 1,264 | 1,296 | 1,306 | -3.2% |
Questions
What was Ultragenyx Pharmaceutical's revenue in Q2 FY2026?
Ultragenyx Pharmaceutical (RARE) reported revenue of $214 million for Q2 FY2026, the quarter ended 30 June 2026, up 28.1% on the same quarter a year earlier.
How much did Ultragenyx Pharmaceutical earn in Q2 FY2026?
Net loss for Q2 FY2026 was $92 million, and the diluted loss per share $0.90.
When did Ultragenyx Pharmaceutical report Q2 FY2026 results?
Ultragenyx Pharmaceutical filed its 10-Q for the quarter ended 30 June 2026 with the SEC on 5 August 2026.
Quarterly results, the last 20 quarters
| Q3 FY2021 | Q4 FY2021 * | Q1 FY2022 | Q2 FY2022 | Q3 FY2022 | Q4 FY2022 * | Q1 FY2023 | Q2 FY2023 | Q3 FY2023 | Q4 FY2023 * | Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 * | Q1 FY2025 † | Q2 FY2025 † | Q3 FY2025 | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.6 | 83.4 | 79.9 | 89.3 | 90.7 | 103 | 100 | 108 | 98.1 | 127 | 109 | 147 | 139 | 165 | 139 | 167 | 160 | 207 | 136 | 214 |
| R&D | 113 | 123 | 143 | 155 | 237 | 171 | 166 | 165 | 157 | 161 | 178 | 162 | 170 | 188 | 166 | 165 | 216 | 203 | 187 | 167 |
| SG&A | 53.9 | 59.4 | 67.3 | 68.1 | 69.8 | 72.8 | 76.6 | 81.4 | 74.9 | 76.8 | 78.2 | 80.6 | 80.4 | 82.5 | 87.0 | 87.0 | 86.6 | 87.9 | 88.0 | 88.0 |
| Operating income | -89.8 | -103 | -137 | -142 | -225 | -146 | -154 | -148 | -145 | -122 | -165 | -116 | -132 | -122 | -143 | -108 | -171 | -113 | -169 | -75.0 |
| Operating margin | -110% | -123% | -171% | -158% | -248% | -141% | -153% | -137% | -148% | -96% | -152% | -79% | -95% | -74% | -103% | -65% | -107% | -55% | -124% | -35% |
| Pre-tax income | -72.8 | -122 | -152 | -158 | -239 | -153 | -163 | -159 | -159 | -127 | -170 | -131 | -133 | -133 | -150 | -114 | -180 | -128 | -184 | -91.0 |
| Net income | -73.0 | -122 | -152 | -158 | -245 | -152 | -164 | -160 | -160 | -123 | -171 | -132 | -134 | -133 | -151 | -115 | -180 | -129 | -185 | -92.0 |
| Net margin | -89% | -147% | -191% | -177% | -270% | -147% | -163% | -148% | -163% | -97% | -157% | -90% | -96% | -81% | -109% | -69% | -113% | -62% | -136% | -43% |
| Diluted EPS | -$1.08 | -$1.78 | -$2.19 | -$2.26 | -$3.50 | -$2.16 | -$2.33 | -$2.25 | -$2.23 | -$1.52 | -$2.03 | -$1.52 | -$1.40 | -$1.39 | -$1.57 | -$1.17 | -$1.81 | -$1.29 | -$1.84 | -$0.90 |
| Operating cash flow | -59.6 | -54.3 | -118 | -77.3 | -95.3 | -90.3 | -157 | -116 | -118 | -83.9 | -191 | -77.0 | -67.0 | -79.5 | -166 | -108 | -91.4 | -99.8 | -197 | -97.0 |
| Capital expenditure | 20.6 | 16.0 | 32.2 | 30.9 | 26.0 | 27.0 | 25.0 | 13.9 | 3.7 | 1.6 | 3.2 | 2.0 | 1.6 | 0.7 | 1.0 | 2.5 | 1.3 | n/a | 1.0 | 1.0 |
| Free cash flow | -80.2 | -70.4 | -150 | -108 | -121 | -117 | -182 | -130 | -122 | -85.5 | -194 | -79.0 | -68.6 | -80.2 | -167 | -111 | -92.7 | n/a | -198 | -98.0 |
| Shares outstanding | 68m | 69m | 70m | 70m | 70m | 70m | 71m | 71m | 72m | 82m | 83m | 92m | 92m | 92m | 94m | 96m | 96m | 97m | 98m | 99m |
| Filing | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.10-Q for the period ended 30 June 2026, filed 5 August 2026: the filing.